Clinical studies of adoptive T-cell therapies.
| Type of T Cell . | Clinical Application . |
|---|---|
| Abbreviations: NK, natural killer; CTL, cytotoxic T lymphocyte; EBV, Epstein-Barr virus; BMT, bone marrow transplantation; NHL, non-Hodgkin’s lymphoma | |
| Unmanipulated donor T cells | Relapse of hematologic malignancy posttransplantation1 |
| T-cell subsets | CD4-selected13 or CD8-depleted14 cells |
| TH2 and TC2 cells15 | |
| T cells nonspecifically activated ex vivo | Donor T cells briefly activated ex vivo and transduced with a suicide gene to treat relapse of hematologic malignancy posttransplantation16,17 |
| T cells activated ex vivo with CD3 and CD2818 | |
| Expanded cytokine-induced killer (CIK) or CD8+ NK-T cells19 | |
| Allodepleted T cells | Postallogeneic transplant to reduce risk of relapse20,21 |
| Antigen-specific CTL | EBV-specific CTL for prophylaxis and treatment of EBV lymphoma post-BMT2,22,23 or solid organ transplantation24;,25 |
| LMP1- or 2-specific CTL for Hodgkin’s disease26 | |
| Leukemia-specific CTL postleukemia relapse27 | |
| Minor antigen-specific CTL postleukemia relapse28 | |
| Chimeric receptor transduced T cell | CD20 chimeric receptor transduced T cells for NHL29 |
| Type of T Cell . | Clinical Application . |
|---|---|
| Abbreviations: NK, natural killer; CTL, cytotoxic T lymphocyte; EBV, Epstein-Barr virus; BMT, bone marrow transplantation; NHL, non-Hodgkin’s lymphoma | |
| Unmanipulated donor T cells | Relapse of hematologic malignancy posttransplantation1 |
| T-cell subsets | CD4-selected13 or CD8-depleted14 cells |
| TH2 and TC2 cells15 | |
| T cells nonspecifically activated ex vivo | Donor T cells briefly activated ex vivo and transduced with a suicide gene to treat relapse of hematologic malignancy posttransplantation16,17 |
| T cells activated ex vivo with CD3 and CD2818 | |
| Expanded cytokine-induced killer (CIK) or CD8+ NK-T cells19 | |
| Allodepleted T cells | Postallogeneic transplant to reduce risk of relapse20,21 |
| Antigen-specific CTL | EBV-specific CTL for prophylaxis and treatment of EBV lymphoma post-BMT2,22,23 or solid organ transplantation24;,25 |
| LMP1- or 2-specific CTL for Hodgkin’s disease26 | |
| Leukemia-specific CTL postleukemia relapse27 | |
| Minor antigen-specific CTL postleukemia relapse28 | |
| Chimeric receptor transduced T cell | CD20 chimeric receptor transduced T cells for NHL29 |